Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Industry News

Biotech Investors Should be Bullish: It’s a Long Road From a Tweet to a Law

Friday, March 24, 2017   (0 Comments)
Share |

The biopharmaceutical industry is under attack. It’s not the first time.


Jim Greenwood


The public has always had a love-hate relationship with drug companies, dating back to the late 1800s. But even in the face of public pressure, Congress has always remained focused on curing disease and has opted against rash policy actions. That constancy has allowed U.S. biotech to lead the world.

Investors don’t do well with uncertainty and they have perceived plenty in recent months coming out of the nation’s capital. The link between Twitter and volatility in the Nasdaq Biotechnology Index predates President Trump.

Read full article via here.



Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal